Knockdown of Med19 Suppresses Proliferation and Enhances Chemo-sensitivity to Cisplatin in Non-small Cell Lung Cancer Cells

Ling Wei¹, Xing-Wu Wang¹, Ju-Jie Sun², Li-Yan Lv¹, Li Xie¹, Xian-Rang Song¹*

Abstract

Mediator 19 (Med19) is a component of the mediator complex which is a coactivator for DNA-binding factors that activate transcription via RNA polymerase II. Accumulating evidence has shown that Med19 plays important roles in cancer cell proliferation and tumorigenesis. The involvement of Med19 in sensitivity to the chemotherapeutic agent cisplatin was here investigated. We employed RNA interference to reduce Med19 expression in human non-small cell lung cancer (NSCLC) cell lines and analyzed their phenotypic changes. The results showed that after Med19 siRNA transfection, expression of Med19 mRNA and protein was dramatically reduced (p<0.05). Meanwhile, impaired growth potential, arrested cell cycle at G0/G1 phase and enhanced sensitivity to cisplatin were exhibited. Apoptosis and caspase-3 activity were increased when cells were exposed to Med19 siRNA and/or cisplatin. The present findings suggest that Med19 facilitates tumorigenic properties of NSCLC cells and knockdown of Med19 may be a rational therapeutic tool for lung cancer cisplatin sensitization.

Keywords: Med19 - non-small cell lung cancer - sensitivity - cisplatin - RNAi

Introduction

Non-small cell lung cancer (NSCLC), a malignant tumor type with a high rate of relapse and metastasis, is the leading cause of cancer-related deaths worldwide. Despite aggressive approaches to treatment of lung cancer, the prognosis of NSCLC patients is still poor, with a 5-year survival rate of 5-14% (Khuri et al., 2001). This is usually due to the fact that most patients with this disease receive a late diagnosis and experience a relapse because of the chemoresistance (Rosell et al., 2006; Jang et al., 2009). Therefore, there is an urgent need to identify novel prognostic marker and therapeutic target for NSCLC.

The mediator (Med) complex, an essential component of the RNA polymerase II (pol II)-mediated transcription complex, plays a crucial role in the stimulation of basal transcription and regulation of eukaryotic mRNA synthesis, which underpins cell proliferation, development, differentiation, and maintenance (Conaway et al., 2005; Conway et al., 2005; Casamassimi et al., 2007). Med is a crescent-shaped complex consisting of head, middle, tail modules and highly conserved from yeast to mammals in evolution (Boube et al., 2002). As a multi-protein coactivator, Med consists of about 30 subunits that can interact with transcriptional activators, such as p53, SP1 and VP16 (Malik et al., 2005; Vojnic et al., 2011). Human Med19 gene, also known as "lung cancer metastasis related protein 1" (LCMR1), is located on human chromosome 11 at the 11q12.1 locus and involved in the head-module subunits of Mediator. Recently, accumulating evidence has shown that Med19 is associated with cancer cell proliferation, tumorigenesis and prognosis, suggesting that Med19 may be an attractive candidate for the therapeutic target of cancer (Chen et al., 2011a; Cui et al., 2011a; Li et al., 2011a; Sun et al., 2011a; Wang et al., 2011a; Zou et al., 2011a; Ji-Fu et al., 2012a; Zhu et al., 2013a; Yu et al., 2014a). In human NSCLC, overexpression of Med19 significantly associated with clinical stage and pathogenesis, indicating that Med19 may have applications in the clinical diagnosis and treatment of lung cancer (Chen et al., 2011b). However, whether Med19 is involved in chemoresistance to cisplatin, a commonly used chemotherapeutic agent in NSCLC treatment, remains largely unknown.

In the present study, we employed siRNA to inhibit the expression of Med19 in NSCLC cells and analyze the biological behaviors. We report for the first time that silencing of Med19 can enhance cisplatin chemosensitivity and apoptosis in NSCLC cell lines. Caspase-3 activity and apoptosis were induced when cells were exposed to Med19 siRNA and/or cisplatin. Our results thus suggest that Med19 inhibition could be a promising approach for chemosensitization of NSCLC cells to applied cisplatin therapy.

¹Shandong Provincial Key Laboratory of Radiation Oncology; ²Department of Pathology, Shandong Cancer Hospital and Institute, Jinan, China *For correspondence: sxr@vip.163.com
**Materials and Methods**

**Cell culture**

Human lung adenocarcinoma cell lines, SPCA1 and A549, were obtained from China Centre for Type Culture Collection (CCTCC, Wuhan, China) and American Type Culture Collection (ATCC, Manassas, VA, USA), respectively. The cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) containing 10% fetal bovine serum (FBS, Gibco), 100 units/mL penicillin and 100 μg/mL streptomycin at 37°C in a humidified atmosphere of 5% CO2.

**Med19 siRNA transfection**

Silencing of Med19 expression was obtained through transfection of med19 siRNA. SiRNA targeting the sequence of human Med19 gene (NM_153450.1) is 5’-GGTGAAGGAGAGCTAAGT-3’, designed with an online software of Invitrogen and has been evidenced to be effective in many reports (Cui et al., 2011b; Li et al., 2011b; Zou et al., 2011b; Li et al., 2011b; Sun et al., 2011b; Wang et al., 2011b; Zhang et al., 2012b; Ji-Fu et al., 2012b; Yu et al., 2014). The sequences for the control siRNA were sense: 5’-UUCUCCGAACGUUCAGCUTT-3’; antisense: 5’-ACGUACACGUUCAGAATT-3’. The indicated siRNA were synthesized by Genepharma (Shanghai, China). Cell transfection was performed using Lipofectamine™ 2000 reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Briefly, NSCLC cells were seeded in six-well plates at a density of (2-3)×10⁴ cells/well and grown overnight. Then, the cells were transfected for the indicated time under standard culture conditions with 100 nM siRNA duplexes using Lipofectamine™ 2000 reagent.

**Real-time RT-PCR analysis**

For real-time RT-PCR analysis, total cellular RNA was extracted with Trizol (Invitrogen). Reverse transcription was performed by Super-Script II reverse transcriptase (TaKaRa code DRR037A, Dalian, China). The Med19 and internal control β-actin gene were amplified with SYBR® Premix Ex Taq™ quantitative PCR kit (Takara code DRR041A, Dalian, China). Primers for Med19 (forward 5’-TGACGAGCCAGCACTC-3’; reverse 5’-CAGTGTCAGGGAGGTAC-3’) and β-actin (forward 5’-TAGGTGCGTACCCTTTC-3’; reverse 5’-GCTGTCCACCTTCACCGT-3’) were synthesized by Sangon (Shanghai, China). Relative expression of Med19 mRNA was calculated using the comparative CT method.

**Immunoblot analysis**

The indicated cells were lysed by precooled lysis buffer containing 0.15 M NaCl, 50 mM Tris-Cl (pH 7.4), 2 mM EDTA (pH 8.0), 0.5% Triton-100, 5 mM DTT, 0.2 mM PMSF and 2 μg/mL aprotinin. Bradford method was applied to determine the protein content. 50 μg total protein lysates were separated by 10% SDS-polyacrylamide gels and the gels were subjected to immunoblotting. The resulting PVDF membrane was blocked in TBST (10 mM Tris [pH 8.0], 150 mM NaCl, 0.05% Tween-20) blocking buffer containing 5% non-fat dry milk. The primary antibodies, rabbit anti-human Med19 (Abcam, Cambridge, UK) and mouse anti-human β-actin (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies were added at a ratio of 1: 400 and 1: 2000, respectively, and incubated overnight at 4°C. The membrane was then washed thrice with TBST, followed by incubation for 1h with appropriate secondary antibody coupled to horseradish peroxidase (Santa Cruz Biotechnology) at room temperature. After further washing, enhanced chemiluminescence (ECL plus, Amersham Pharmacia Biotech) reagents were used to detect the signals, according to the manufacturer’s instructions.

**Cell cycle analysis**

To determine whether Med 19 silencing affected cell cycle progression, NSCLC cells were transfected with Med19 siRNA for 72 h. Then, the indicated cells were fixed in 70% ethanol at 4°C overnight. Next, cells were washed twice with cold PBS and stained with a solution containing 50 μg/mL propidium iodide (PI) and 100 μM RNase A in PBS for 30 min in the dark at room temperature. Flow cytometric analysis was performed on a FACS Calibur flow cytometer (BD Bioscience, CA).

**Cell proliferation assay**

For determination of cell growth, [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)] assay was used. Cells transfected with Med19 siRNA for 48 h were seeded in 96-well plates at a density of 3000 cells per well. After incubation for 24, 48, 72 and 96h, 20 μL of MTT (5 mg/mL) was added. After 4 h of incubation, 100 μL of 10% dimethyl sulfoxide (SDS) containing 0.01N HCL was added to each well. After being incubated for 24 h at 37°C, the absorbance was measured at 570 nm with a microplate reader (Bio-rad 680, USA).

**Colony formation assay**

Cells transfected with Med19 siRNA for 48 h were seeded in 6-well plates with 200 cells per well and cultured at 37°C for 14 days. The cell colonies were counted. Visible colonies (containing 50 or more cells each) were counted. All clonogenic assays were repeated as independent experiments at least twice.

**Cisplatin sensitivity evaluation via MTT assay**

After transfected with Med19 siRNA for 48h, the indicated cells were trypsinized and plated into 96-well plates at a density of 10⁴ cells/well, followed by treatment with the indicated doses of cisplatin (0, 0.625, 1.25, 2.5, 5, 10 μg/mL) for 24h. Then, cells were incubated with 20 μL of MTT (5 mg/mL) for 4 h at 37°C. Finally, the resulting formazan crystals were solubilized with 100 μL of 10% SDS containing 0.01N HCL. Absorbance was measured at 570 nm by a microplate reader (Bio-Rad 680, USA), and the cell viability was calculated.

**Determination of apoptosis by flow cytometry**

To determine the effect of Med19 depletion on
apoptosis, NSCLC cells were transfected with Med 19 siRNA for 48 h, followed by exposure to the indicated concentration of cisplatin (2 μg/ml) for 24h. Subsequently, cells were stained with Annexin V-FITC Apoptosis Kit (BD Pharmingen, CA) and subjected to FACS Calibur flow cytometer.

**Caspase-3 activity assay**

A caspase-3 activity assay kit (Beyotime Institute of Biotechnology, Haimen, China) was used to evaluate the caspase-3 activity of lung cancer cells, according to the manufacturer’s protocols. After treatment with cisplatin for 24 h, the indicated cells were washed with ice-cold PBS and homogenized in lysis buffer. Lysates were centrifuged at 16,000 g for 10 min, and Bradford protein assay was used to determine protein concentrations. 30 μg of protein was incubated with 10μl of Ac-DEVD-pNA at 37°C for 4 h in a 96-well microtiter plate. Samples were measured with an ELISA reader at an absorbance of 405 nm.

**Statistical analysis**

Data were presented as mean±SD. SPSS 13.0 software (SPSS, Chicago, USA) was used to perform statistical analysis. Statistical significance was set at p<0.05.

**Results**

**Med19 siRNA specifically inhibits the expression of Med19 mRNA and protein in lung cancer cells**

Real-time RT-PCR was applied to assess the Med19 mRNA expression in parental cells, control or Med19 siRNA transfected NSCLC cells. As shown in Figure 1A, the expression of Med19 mRNA in Med19 siRNA group were significantly down-regulated compared with control siRNA group (p<0.05). No statistical significances were observed between control siRNA and parental cells (p>0.05). Moreover, Med19 siRNA transfected cells exhibited significant reduced levels of Med19 protein compared with control siRNA and parental cells (p<0.05; Figure 1B). At the same time, another Med19 siRNA also demonstrated similar RNAi efficacy (data not shown). The sequences for this Med19 siRNA were as follows: sense: 5' -CGAUAUCGAUCACACUATT -3'; antisense: 5' - UAGUGUGUGACGAUUCGTT-3'.

**Med19 knockdown leads to impaired cell proliferation and colony formation of NSCLC cells**

Two days after transfection, all three groups of SPCA1 and A549 cells were plated for MTT and colony formation assays to observe cell growth. Compared with control siRNA, the proliferation of Med19 siRNA transfected cells were dramatically suppressed (Figure 2A). In colony formation assay, similar results were obtained. Both NSCLC cells exhibited reduced colony formation potentials in Med19 siRNA cells (Figure 2B). These findings indicate that knockdown of endogenous Med19 inhibited the proliferation of NSCLC cells.

**Knockdown of Med19 induces apoptosis and regulates cell cycle progression**

In order to evaluate the effect of Med19 on apoptosis and cell cycle distribution, flow cytometry assay was performed. As shown in Figure 3A, Med19 silencing increased apoptosis compared with control siRNA group (p<0.05), indicating that Med19 influenced the process of apoptosis. In the profile of cell cycle distribution, the percentage of G0/G1 phase was increased in Med19 siRNA treated cells (SPCA1, control vs. Med19 siRNA, 67.8±3.8 vs 75.8±4.3, p<0.05; A549, control vs. Med19 siRNA, 59.5±3.3 vs 67.2±3.6, p<0.05), whereas the percentage of S phase was decreased in these cells compared with control siRNA cells (SPCA1, control vs. Med19 siRNA, 21.5±1.6 vs 15.8±1.8; A549, control vs.

**Figure 1. Med19 siRNA Mediated RNAi Dramatically Suppressed Med19 Expression in Lung Cancer Cells.**

(A) Expression of Med19 mRNA detected by real-time RT-PCR. Compared with Parental cells and control siRNA group, Med19 mRNA expression dramatically decreased in Med19 siRNA group. *p<0.05: Med19 siRNA versus control siRNA; (B) Immunoblot analysis of Med19 protein expression. β-actin was used to an internal control. Med19 protein expression was significantly lower in Med19 siRNA group. *p<0.05: Med19 siRNA versus control siRNA

**Figure 2. Knockdown of Med19 Attenuated Cell Growth of SPCA1 and A549 Cells.** (A) Influence of Med19 knockdown on proliferation of SPCA1 and A549 cells were detected by the MTT assay. *p<0.05: Med19 siRNA versus control siRNA. (B) Effect of Med19 knockdown on growth of SPCA1 and A549 cells were detected by the colony formation assay. *p<0.05: Med19 siRNA versus control siRNA
Med19 siRNA, 29.8±2.0 vs 22.3±1.7, p<0.05) (Figure 3B). These results indicated that Med19 regulated cell cycle progression at the G1/S boundary.

Med19 silencing increases cisplatin sensitivity, cisplatin-induced apoptosis and caspase-3 activity in NSCLC cells

To determine the effect of Med19 silencing on cisplatin sensitivity of NSCLC cells, the indicated cells were treated with various concentrations of cisplatin for 24h. Our results showed that the viability of Med19 silenced cells were more decreased than that of control siRNA treated cells at the same concentration of cisplatin (Figure 4A), indicating that Med19 inhibition may enhance the sensitivity to cisplatin in NSCLC cells. To explore the effect of Med19 silencing on cisplatin-induced apoptosis, we detected apoptosis using a standard Annexin V assay. A significant increase in cisplatin-induced apoptosis was observed in cells transfected with Med19 siRNA, compared with control siRNA transfected cells (Figure 4B and 4C). These results revealed that Med19 depletion potentiates cisplatin sensitivity and promotes cisplatin-induced apoptosis. As caspase-3 is a critical enzyme of the execution phase of apoptosis, we investigated the influence of Med19 silencing on caspase-3 activity. Data showed that caspase-3 is highly activated in Med19 siRNA treated cells compared with the control cells after cisplatin treatment (Figure 4D).

**Discussion**

Emerging evidence has demonstrated that Med19 is a novel proliferation regulator that promotes cancer cells growth and tumorigenesis, including cancers of breast, bladder, colorectal and lung (Sun et al., 2011c; Li et al., 2011c; Zou et al., 2011c; Xu et al., 2012; Zhang et al., 2012c; Ji-Fu et al., 2012c; Zhu et al., 2013b; Wen et al., 2013). Recently, it was reported that Med19 was strongly overexpressed in cancer tissues of NSCLC patients and the expression was significantly associated with clinical stage (Chen et al., 2011c). However, the detailed biological effects of Med19 on NSCLC, especially the relation between Med19 and chemosensitivity to cisplatin, has not been clarified.

In this study, we disclosed that suppression of Med19
results in impaired potentials of proliferation and colony formation in NSCLC cells (Figure 1), indicating that Med19 plays an important role in cell growth. Similar with the results from cells of breast cancer and hepatocellular carcinoma (Zou et al., 2011d; Zhang et al., 2012d). We also found that Med19 down-regulation elicited augmentation of G0/G1 phase proportion, showing that Med19 may be involved in control of post-mitotic cellular process in NSCLC. The G1 checkpoint is controlled by cyclin D, p21 and CDK4/6 (Satyanarayana et al., 2008; Wang et al., 2012). Whether Med19 contributing to the activity of CDK4/6-Cyclin D complexes in NSCLC cells needs to be further elucidated.

Chemotherapy based on cisplatin, the most widely used regimen in NSCLC first-line chemotherapy, plays a crucial role in NSCLC comprehensive treatment. However, inherent and acquired drug resistance limited therapeutic efficacy. It has been shown that cisplatin resistance is associated with multifactorial mechanisms, such as inactivation by glutathione, metallothionein, or other sulphur-containing molecules, increased repair of DNA damage and Autophagy, reduced apoptosis and intracellular drug accumulation by changing the profile of drug-influx or -efflux molecules (Song et al., 2012; Galluzzi et al., 2012; Zhang et al., 2013). Many studies, concerned with the specific gene manipulation, have provided a way to make cancer cells specifically more sensitive to cisplatin (Hu et al., 2012; Li et al., 2012; Yu et al., 2013). However, the role of Med19 in chemotherapeutic drug resistance has not yet been established. This work was the first study to demonstrate that Med19 silencing enhances chemosensitivity to cisplatin and sensitizes NSCLC cells to cisplatin-induced apoptosis, indicating that Med19 inhibition is applicable to developing combination chemotherapy of cisplatin.

Activation of caspase-3 is a key and common event of two major apoptosis signaling pathways, mitochondrial pathway and death receptor pathway (Mazumder et al., 2008; Snigdha et al., 2012). The death receptor pathway activates initiator caspase-8 and then cleaves its downstream effector caspas, such as caspase-3 which transducts the apoptosis signal, while the mitochondrial pathway is initiated by the mitochondrial dysfunction and then causes activation of caspase-9 which triggers caspase-3 activation (Fulda et al., 2006). Studies have shown that Med19 knockdown results in the upregulation of Bax and downregulation of Mcl-1 (Xu et al., 2012). In human prostate cancer cells PC-3 and DU145, knockdown of Med19 induced apoptosis via modulation of Bid and Caspase 7 (Cui et al., 2011c). Recent evidence has shown that Med19 knockdown can induce apoptosis in osteosarcoma cell line Saos-2 via induction of caspase-3 and poly ADP-ribose polymerase (PARP), along with the downregulated expression of cyclin D1 and cyclin B1 (Yu et al., 2014). Inhibition of cyclin D1 enhanced cisplatin sensitivity have been documented in human breast cancer MCF-7 and human oral squamous cell carcinoma cells. The present data demonstrated that combination of Med19 siRNA and cisplatin led to caspase-3 catalytic activity in NSCLC cells to a level that was dramatically higher than that observed with cisplatin alone. Apoptotic pathway and related protein molecules involved in Med19 silencing enhancing cisplatin-induced apoptosis and sensitivity of NSCLC cells need to be further investigated.

Taken together, the present data has identified that siRNA-mediated Med19 down-regulation attenuates the carcinogenic properties of NSCLC cells. To the best of our knowledge, this is the first report to present a siRNA-mediated Med19 silencing strategy to potentiate chemosensitivity and apoptosis induced by cisplatin. These findings indicate that combination of Med19 down-regulation and cisplatin may be a new therapeutic strategy for NSCLC. However, this study has limitations. We only focused on a chemotherapeutic drug cisplatin, further investigation on other chemotherapeutic agents might strengthen the significance of our study.

Acknowledgements

This research is supported by grants from Shandong Province Natural Science Foundation (ZR2009CM141, ZR2010HM083) and Shandong Health Department (2011HZ095), China.

References


